Trial Profile
A randomized Phase 2 study of Imprime PGG and durvalumab combination in head and neck squamous cell carcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2018
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Odetiglucan (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Biothera
- 16 Sep 2018 New trial record
- 05 Sep 2018 According to a Biothera media release, the company expects to initiate the study in the second half of 2018. The trial will be conducted at several clinical sites, including Sanford Health, USA. Completion of patient enrollment is expected in 2019.